AstraZeneca reports Q4 core EPS $1.56, consensus $1.41 Reports Q4 revenue $7.28B, consensus $7.17B. Reports Q4 Nexium revenue $1.05B vs. $1.07B a year ago, Crestor revenue $1.62B vs. $1.77B a year ago, Symbicort revenue $891M vs. $839M a year ago.
News For AZN From The Last 14 Days
Check below for free stories on AZN the last two weeks.
Leerink's biotech/pharma analysts hold an analyst/industry conference call Biotech Analyst Kozul and Major Pharmaceuticals Analyst Fernandez provide a review of Emerging 3rd Generation Tyrosine Kinas Inhibitors (TKI) Data for Non-Small Cell Lung Cancer (NSCLC) on an Analyst/Industry conference call. Relevant companies AstraZeneca (AZN) and Clovis Oncology (CLVS) may be discussed on the Analyst/Industry conference call to be held on December 12 at 1 pm.